POINT Biopharma Global Inc.

The surge of interest in radiopharmaceuticals for both diagnostics and therapeutics is likely to prove very beneficial for Germany’s PentixaPharm GmbH which has a promising treatment for CNS lymphom

South Korea's SK Biopharmaceuticals Co., Ltd is looking to continue its growth story via a new diversification into the globally hot area of radiopharmaceuticals through a licensing agreement with C

Radionetics Oncology , a three-year-old start-up that has raised $82.5m to date, landed a sweet deal with Eli Lilly and Company , with the big pharma paying $140m up front for an exclusive right to b

It has felt lately that there may be not be enough radiopharmaceutical companies to satisfy big pharma’s appetite. First, in December 2023, Eli Lilly and Company purchased POINT Biopharma Global In